Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2017 | Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome

Maria Teresa Voso, MD, from University Tor Vergata Rome, Rome, Italy, discusses the use of conventional chemotherapy and hypomethylating agents before allogeneic hematopoietic stem cell transplant (HSCT) at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. She explains that a large proportion of patients can undergo HSCT, but that a bridging treatment may be required while this is organized. Dr Voso discusses which patient subgroups may most benefit from hypomethylating agents and chemotherapy, but concludes that the two treatments need to be compared in a randomized prospective study.